 Entera Bio Ltd NASDAQ: ENTX shares are trading higher by 47.66 at 6.63 Wednesday after the company announced the topline Phase 2 clinical trial of EB613 met its primary and key secondary endpoints. Entera Bio says an end-of-Phase 2 meeting with the FDA to review the EB613 development program is anticipated in the coming months. 